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Summary
In high-income countries, more than 90% of children with
mature B-cell lymphomas are cured with frontline therapy.
However, cure requires prompt and correct diagnosis, careful
risk stratification, very intense chemotherapy and meticulous
supportive care, together with logistical support for patients
who live far from the cancer centre or face financial barriers to
receiving care. In low- and middle-income countries (LMIC),
cure rates range from 20% to 70% because of lack of diagno-
sis, misdiagnosis, abandonment of treatment, toxic death and
excess relapse with reduced-intensity regimens. Fortunately, a
wide range of successful interventions in LMIC have reduced
these causes of avoidable treatment failure. Public awareness
campaigns have led to societal awareness of childhood cancer;
telepathology has improved diagnosis, even in remote areas;
subsidized chemotherapy, transportation, housing and food
have reduced abandonment; and hand hygiene, nurse training
programmes and health system improvements have reduced
toxic death. These interventions can be deployed everywhere
and at low cost, so are highly scalable. Children and adoles-
cents with Burkitt lymphoma can be cured in all countries by
making a timely correct diagnosis, applying protocols adapted
to the local context, preventing abandonment of therapy and
avoiding toxic death. Reducing these causes of treatment fail-
ure is feasible and highly cost-effective everywhere.
Keywords: non-Hodgkin lymphoma, Burkitt lymphoma,
B-cell lymphoma, low-income countries, middle-income
countries, abandonment, toxic death.
Non-Hodgkin lymphomas (NHL) are some of the most com-
mon and curable paediatric cancers in the world, with an esti-
mated 56 000 new diagnoses each year among children 0–
19 years old (Steliarova-Foucher et al, 2017). In high-income
countries (HIC), advances in diagnosis, risk-stratification,
optimization of protocols, control of central nervous system
disease and supportive care have significantly improved the
prognosis of children with NHL over the recent decades (Min-
ard-Colin et al, 2015). Data generated by international cooper-
ative groups has enabled tailoring the treatment intensity and
clarified the need for various treatment components for speci-
fic NHL subtypes, tumour burden and disease extent (Minard-
Colin et al, 2015). In HIC, intensive chemotherapy regimens
can be delivered with toxic death rates of 2% or lower, such
that approximately 90% of children with NHL are cured with
frontline therapy (Minard-Colin et al, 2015). Furthermore,
new drugs and immune therapies have improved salvage rates
for the 8% who relapse, and some of these survive long-term,
even after high-risk relapses (Cairo et al, 2018).
Unfortunately, the outlook in areas with limited resources
is less optimistic, and 90% of children live in such settings
(Fig 1, http://www.worldpopdata.org/map). In low- and mid-
dle-income countries (LMIC), avoidable treatment failure
results from delayed or even lack of diagnosis, misdiagnosis,
abandonment of therapy, excess toxic death and excess
relapse due to insufficiently intensive regimens, such that
event-free survival (EFS) ranges from 0% to 30% in much of
the world (Fig 2) (Hesseling et al, 2013; Gross & Biondi,
2016; Gopal & Gross, 2018). Fortunately, each of these causes
of avoidable treatment failure can be reduced with proven
strategies, as discussed in this review. In most LMIC settings,
children experiencing relapses are incurable, so all efforts
must be concentrated on achieving cure with frontline ther-
apy. For this review, we focus on the management of mature
B-cell lymphomas as these are by far the most common in
LMIC and offer the greatest opportunity to reduce treatment
failure and save lives. The terms “mature B-cell lymphomas”
and “Burkitt lymphoma” are used interchangeably.
Epidemiology
There are major variations in the epidemiology of Burkitt
lymphoma, with reported annual incidences ranging from 4
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to 60 cases per 1 000 000 children depending on the setting,
a 15-fold difference based on geographic, ethnic and environ-
mental factors (Stefan & Lutchman, 2014; Steliarova-Foucher
et al, 2017). Endemic Burkitt lymphoma is highly prevalent
in tropical Africa and, despite its presentation as relatively
localized disease in many cases, EFS is lower than 50%,
Fig 1. The number of children with cancer per capita is highest in low- and middle-income countries. This map shows the cases of cancer per
million people (adults and children) in the population and highlights the relatively high burden of childhood cancer in the poorest countries.
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Fig 2. Causes of treatment failure in children with Burkitt lymphoma in selected centres and countries in high- middle- and low-income coun-
tries. Causes of treatment failure represent the first adverse event. Many of these causes lead to other subsequent causes of second and third treat-
ment failure, as in the case of patients who abandon treatment then relapse, or those who are misdiagnosed and whose disease then progresses
while on inappropriate treatment. Figure used with kind permission of Scott C. Howard, MD, MSc.
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mostly because of comorbid conditions such as malnutrition
and infection, low availability of resources for treatment,
suboptimal supportive care, and logistical and financial
obstacles that lead to treatment abandonment (Traore et al,
2011; Marjerrison et al, 2012; Gopal & Gross, 2018; Neal
et al, 2018). However, it is uncertain if it shares the exquisite
chemosensitivity shown by sporadic Burkitt lymphoma
because there have been no reported results of clinical trials
for children with endemic Burkitt lymphoma treated with
intensive regimens. There is a close association between
Epstein–Barr virus (EBV) infection and endemic Burkitt lym-
phoma and virtually all patients with endemic Burkitt lym-
phoma harbour EBV sequences in the tumour genome
(Brady et al, 2007). Concomitant malaria infection, initially
reported many decades ago, has more recently been better
characterized (Johnston et al, 2014). Also, there is also an
increased risk for Burkitt lymphoma in children living in
areas where human immunodeficiency virus (HIV) infection
is highly prevalent (Mutalima et al, 2008), adding additional
co-morbidity that could affect outcome. However in a study
from Cameroon, the overall prevalence of HIV in children
with Burkitt lymphoma was comparable to the general popu-
lation (Hesseling et al, 2018). In middle-income countries
(MIC), there is no evidence of increased incidence in Burkitt
lymphoma compared to the Western world, and there are no
striking differences in clinical presentation compared to
higher-income countries, where the most common site of
involvement is the abdomen (Ferreira et al, 2012; Steliarova-
Foucher et al, 2017). In fact, differences in sites of presenta-
tion in sub-Saharan Africa may be partly due to the use of
clinical staging only in many areas with few resources.
Patients with abdominal disease who present with an acute
abdomen may die without having a diagnosis of lymphoma
made, while those with jaw involvement or other head and
neck manifestations (e.g. ocular) would rarely die before
being diagnosed. The relationship with EBV infection is com-
parable to that in HIC, but specific molecular features have
been reported in some MIC (Liao et al, 2018; Uccini et al,
2018). There is far less information about the epidemiology
and results in other lymphoma subtypes, such as lym-
phoblastic lymphomas or large cell lymphomas, including
anaplastic large cell lymphomas (ALCL), in LMIC (Ceppi
et al, 2016). In addition, there is relatively little known about
certain lymphoma subtypes that are rare in Western coun-
tries, such as natural killer (NK) cell cancers, which are
much more common in specific regions of LMIC, including
East Asia and some Latin American countries (Pillai et al,
2016). However, the specific epidemiology, management and
outcomes of these other types of NHL will not be addressed
here.
Protocol-based care
Children with cancer are typically treated either on a research
protocol or according to a published regimen. The “best”
regimen has not been determined, but several strategies
achieve 90% cure rates in HIC (Reiter et al, 1999; Patte et al,
2001, 2007; Woessmann et al, 2005; Minard-Colin et al,
2015; Allemani et al, 2018). Regimens for Burkitt lymphoma
include several key components, though details for each may
differ by study group (Table I). After a careful evaluation of
disease extent with imaging studies, bone marrow biopsy,
evaluation of the cerebrospinal fluid and the use of lactate
dehydrogenase (LDH) as a surrogate for tumour burden,
patients are treated with intensive chemotherapy regimens
(Reiter et al, 1999). Most regimens include a cytoreductive
pre-phase, used at the initiation of therapy in order to
administer a lower dose of chemotherapy that allows the ini-
tial stabilization of the patient and reduces risk of tumour
lysis syndrome (TLS) and toxic death (Howard et al, 2011).
This is usually followed immediately by a 5-day high-dose
multi-agent chemotherapy block that aims to deliver the
highest intensity treatment to maximize tumour response. In
fact, the ability to deliver 2 blocks of intense therapy within
21 days of starting the first block is associated with improved
outcomes. This is not surprising considering how rapidly
Burkitt lymphoma can grow, such that any treatment gaps
provide an opening for disease to progress (Patte et al,
2001). The intense block regimens in HIC include high-dose
methotrexate, alkylating agents, anthracyclines, vincristine,
glucocorticoids and intrathecal methotrexate in doses that
induce severe neutropenia, lymphopenia, thrombocytopenia
and mucositis, requiring intense supportive care including
management of infection, haemorrhage, drug-specific toxici-
ties and nutrition (Patte et al, 2001; Howard et al, 2005,
2016; Gavidia et al, 2012; Israels et al, 2013; Bhojwani et al,
2014; Gupta et al, 2015; Ladas et al, 2016). Patients usually
develop profound aplasia and opportunistic infections, which
necessitate rapid access to intensive life-support. Complete
remission is usually obtained after two of these blocks, fol-
lowed by consolidation therapy. Treatment duration is short,
and most patients complete treatment after 4 or 6 blocks
given every 2–3 weeks. However, implementing this intensive
strategy involves overcoming many challenges at each step,
and in many low-income countries (LIC) it is simply not
feasible, and lower dose regimens are the only alternative
(Depani et al, 2015; Buckle et al, 2016; Stanley et al, 2016).
Although such regimens yield EFS lower than the 90%
achieved in HIC, they allow a subset of patients to be cured
without excess toxicity and are feasible even in the most
basic healthcare systems (Howard et al, 2007a,b, 2017, 2018).
Management of Burkitt lymphoma in low- and
middle-income countries
Many factors contribute to treatment failure in LMIC,
including lack of diagnosis, misdiagnosis, abandonment of
treatment, toxic death and excess relapse with reduced-inten-
sity regimens (Fig 2). In LIC where endemic Burkitt lym-
phoma is prevalent, the diagnosis is often based on clinical
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findings and occasionally confirmed by fine needle aspiration
cytology because many centres’ pathology departments lack
access to immunohistochemistry and molecular testing (Hes-
seling et al, 2012; Gopal & Gross, 2018). In LMICs where
sporadic Burkitt lymphoma is more prevalent, most patients
are biopsied, but when immunohistochemical and molecular
characterization of the different lymphoma subtypes is not
available, many cases may be classified as a different type of
lymphoma, or even as a sarcoma or other cancer type. In
these cases, the differential diagnosis of B-precursor lym-
phoblastic lymphoma from mature B-cell (Burkitt) lym-
phoma may not be possible, and patients may be
inappropriately treated on a generic “NHL” protocol, or
worse, on a protocol for a completely different type of can-
cer. Even in more advanced settings, immunophenotyping
may be preferentially available only at select academic or uni-
versity centres (Wiangnon et al, 2011; Tan et al, 2013). Some
studies from LMIC settings have shown up to 24% discrep-
ancy in samples thought to be Burkitt lymphoma by fine
needle aspiration when submitted for second pathology
review (Naresh et al, 2011). In some settings, as previously
described in Sierra Leone, less than 50% of patients with sus-
pected Burkitt lymphoma achieve a verified diagnosis (San
Roman et al, 2013). Not only is diagnosis problematic in
LMIC, but staging and risk stratification can also present dif-
ficulties. Lack of imaging modalities may make detection of
all sites of disease difficult, and the added cost of performing
lumbar puncture and bone marrow biopsy to fully stage each
patient may make complete staging economically unfeasible.
Tailoring therapy according to LDH values in abdominal
lymphomas has been challenging in international cooperative
studies due to laboratory differences, but it should be possi-
ble to adapt this readily available marker for use in LMIC
(Harif et al, 2008).
Advanced disease at presentation and resource
limitations for the management of initial complications
Toxic death in the first month of therapy can be as high as
10% (Acquatella et al, 2004; Gaytan-Morales et al, 2018) but
it may be up to 30% in higher-risk patients in LMIC
(Ahmad et al, 2010). Delayed diagnosis contributes to every
cause of treatment failure. Patients whose diagnosis is
delayed present with more advanced disease and a higher risk
of malnutrition, TLS, comorbid infections and great risk for
early toxic death (Cervio et al, 2012). In some cases, 2–5%
of patients died within a few hours of arrival to the hospital
before even completing staging evaluation (Moleti et al,
2011; Gaytan-Morales et al, 2018). Extensive abdominal sur-
gical procedures as well as nutritional deficiencies in some
settings may also increase the risk of early toxicity, and
chemotherapy dose modifications may be necessary in these
cases (Israels et al, 2009; Traore et al, 2011; Cervio et al,
2012; Patte et al, 2015; Pribnow et al, 2017; Howard et al,
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increases the risk of toxic death and excess relapse, but also
increases the costs and morbidity of treatment, which in turn
increases the rate of abandonment of therapy. Indeed, in
HIC and some cancer types in LMIC, a delay in diagnosis
has not been associated with reduced cure rates (Howard &
Wilimas, 2005; Lins et al, 2012). However, such studies do
not account for the extreme delays in diagnosis that occur in
some LIC, where the most severe cases are never diagnosed
at all because they succumb to metabolic complications or
comorbid illness before a cancer diagnosis can be made
(Moleti et al, 2011; Gaytan-Morales et al, 2018) (Figs 2 and
3). For example, in one study in Pakistan, children with
NHL presented with stage 3 disease in 91% of cases and
stage 4 disease in the remainder, stages that are associated
with much higher morbidity, mortality, and costs of care
(Faizan et al, 2018).
Intensive chemotherapy is needed to achieve a maximum
anti-lymphoma effect for high survival rates, but in settings
Fig 3. Interventions to address each cause of treatment failure for children with Burkitt lymphoma in low- and middle-income countries. (A)
Examples of interventions for all causes of treatment failure. (B) Examples of interventions to prevent refusal and abandonment of therapy.
Figure used with kind permission of Scott C. Howard, MD, MSc.
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with limited resources, this may not be feasible because of
the aforementioned factors. Renal failure at diagnosis is more
prevalent in LMIC than in HIC and predicts toxic death in
patients treated with a modified Berlin-Frankfurt-Munster
(BFM)-based regimen (Cervio et al, 2012). Therefore, sup-
portive care during the first few weeks of diagnosis is one of
the biggest challenges in LMIC. Use of a low-intensity pre-
phase, intensive nutritional support, management of infec-
tions and aggressive hydration to prevent TLS effectively
reduces early toxic death. Rasburicase improves renal out-
comes and reduces the risk for TLS, and is increasingly avail-
able in MIC, but rarely in LIC (Cairo et al, 2010). Deciding
when to start chemotherapy and with which agents is a key
decision in this setting. The Asociacion de Hemato-
Oncologıa Pediatrica de Centroamerica (AHOPCA) proposed
the use of a second pre-phase in patients with tumour lysis
or other complications, such as severe infection, a strategy
that provides an extra week to stabilize and support the
patient prior to intense chemotherapy (Pe~na-Hernandez
et al, 2019). Omitting methotrexate from the initial block
may be wise, especially in settings where no drug levels are
available, when renal failure occurs, or when ascites or a
pleural effusion are present, as these can serve as a reservoir
for methotrexate and delay its elimination, with potentially
fatal results. In addition to the specific therapeutic strategies
described above, real-time access to experts has also
improved individual patient outcomes. Members of
AHOPCA conduct weekly online meetings for case discussion
that includes the participating centres, data managers and
specialists from St Jude Children0s Research Hospital. Advice
is provided on a weekly basis and by email or phone when
an urgent patient care issue manifests, support that is espe-
cially important during initial patient management (Howard
et al, 2007b; Pe~na-Hernandez et al, 2019).
Inability to use high-dose chemotherapy regimens and
need to modify published effective regimens
Most reports from upper middle-income countries (UMIC),
usually regarding patients treated in referral institutions,
showed that toxic mortality, especially during remission
induction, is higher than in the protocols from major coop-
erative groups in HIC (Acquatella et al, 2004; Klumb et al,
2004; Celkan et al, 2010). In order to design an effective
therapy for Burkitt lymphoma in LMIC, one must weigh the
risk of toxic death against that of excess relapse when consid-
ering chemotherapy intensification. Improved anti-lymphoma
responses have been achieved with higher intensity treat-
ments, which are necessarily associated with an increased risk
of toxic mortality in LMIC (Fig 2). There is no proven supe-
riority of any treatment strategy compared to others in less
developed countries, and the “best” regimen varies not only
by country, but by the specific treatment centre and, most
importantly, the individual patient circumstances and disease
characteristics. Hence, in MIC, treatment regimens were
adapted from the original protocols developed by cooperative
groups in HIC, mainly involving reduction in the dose of
methotrexate and alkylating agents in order to reduce toxic-
ity. Centres in MIC typically use modified BFM regimens, or
in some cases modified French-American-British protocols
(Acquatella et al, 2004; Klumb et al, 2004). The dose of
methotrexate in the BFM regimen blocks AA and BB was
reduced from 5 g/m2 in a 24-h infusion, as per the original
BFM protocol, to 1–3 g/m2 in 3- to 24-h infusions. The
NHL-BFM-95 study showed that shortening the infusion
duration of methotrexate was less toxic than the 24-h infu-
sion, and many LMIC centres now use 4-h infusions rou-
tinely to reduce toxic death (Woessmann et al, 2005).
Rituximab has been added to this regimen by some groups,
with encouraging results (Samochatova et al, 2014). Ritux-
imab is an attractive agent given its lack of haematopoietic
toxicity and its specific mechanism of action against CD20-
positive lymphomas. It can be added to lower-intensity
chemotherapy regimens to increase their efficacy without
adding substantial toxicity (Akbayram et al, 2010; Goldman
et al, 2014). Unfortunately, its high cost makes it unafford-
able in many settings. Results from a single centre in Argen-
tina, where the dose of methotrexate in the first induction
block was reduced to 1 g/m2 in a 4-h infusion while adding
rituximab (4 weekly doses starting from week 1) for high risk
patients demonstrated a decrease in early death and
improved survival (Sanchez La Rosa et al, 2016). However, it
is important to be aware of the high risk of hypogammaglob-
ulinaemia associated with rituximab administration, and the
importance of immunoglobulin replacement therapy for defi-
cient patients to reduce the risk of severe infections.
Although rituximab was not associated with severe infections
in children with Burkitt lymphoma in HIC, it has been asso-
ciated with higher rates of hypogammaglobulinaemia and
toxic death in some LMIC (Chantada, personal communica-
tion). In general, high-risk patients should be better managed
as in-patients until the second chemotherapy block is given
and all these issues are resolved. Careful and consistent infec-
tion prevention practices and timely evaluation along with
early antibiotic treatment, antifungal therapy and granulocyte
colony-stimulating factor support as appropriate are also rec-
ommended. In some settings, as adopted by the French-Afri-
can Paediatiric Oncology Group (GFAOP), intestinal parasite
therapy is routinely given prior to the start of lymphoma
therapy, with standardized recommendations for antimicro-
bial management during therapy (Traore et al, 2011). Gener-
ally, modified (reduced intensity) induction regimens were
associated with lower fatal toxicity rates when compared to
previous experience in the same centres (Sanchez La Rosa
et al, 2016). However, shorter methotrexate infusions are not
only less toxic, but also less effective in controlling the lym-
phoma, and this approach to improve patient survival has
not been studied in a randomized trial. However, not every
centre in MIC uses modified regimens. Reports from selected
(specialty) centres in Brazil and China did not show an
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increased risk of toxic deaths in their cohorts using unmodi-
fied regimens (Klumb et al, 2004; Sun et al, 2006). However,
in these series a higher proportion of lower-risk patients were
included, who typically have low rates of toxic death regard-
less of the setting. Comparative analysis of overall survival
results between reports from HIC and LMIC are also limited
by the different proportion of high-risk patients in the latter.
In most LMIC there is a higher prevalence of advanced dis-
ease, as high as 80–90% of patients in some studies com-
pared to 66% in the BFM-95 protocol (Woessmann et al,
2005; Ahmad et al, 2010; Gaytan-Morales et al, 2018). Some
results from single institutions in UMIC also document a
high prevalence of advanced disease, while others showed a
similar pattern to HIC (Klumb et al, 2004; Sanchez La Rosa
et al, 2016). Finally, the BFM-95 intense chemotherapy block
CC, containing high-dose cytarabine, steroids and etoposide,
is not uniformly used, or is used with lower doses in order
to avoid its higher haematopoietic and gastrointestinal toxic-
ity in many MIC (Cervio et al, 2012). It is important to
maintain a high dose-intensity by compressing the interval
between chemotherapy cycles to the shortest possible, espe-
cially in high-risk patients, by administering the cycles every
2 weeks. However, this interval between cycles is, in practice,
typically longer in LMIC (Chantada et al, 1997). Finally,
relapse risk can be increased by factors unrelated to the treat-
ment regimen, including drug shortages, lack of adherence
and decreased dose-intensity due to comorbid illness, all of
which occur more commonly in LMIC (Fig 3) (Cohen et al,
2018; Khetrapal Singh & Travis, 2018; Perehudoff et al, 2018;
Roth et al, 2018). Fortunately, many interventions have been
documented to decrease each cause of treatment failure (see
Fig 3 for examples).
Treatment abandonment
Treatment abandonment, defined as 4 weeks or more of
missed appointments during therapy, is a major contributor
to treatment failure in less developed countries (Mostert
et al, 2011). Abandonment of therapy has been reported by
most centres in LMIC, but it is quite uncommon in HIC
(Gupta et al, 2013; Friedrich et al, 2015). In some settings,
abandonment has been described as the dominant challenge
for children with NHL, affecting up to half of the children
diagnosed, particularly in rural settings, such as in parts of
Zambia (de Boer et al, 2009). In Iraq, treatment abandon-
ment was a major contributor to treatment failure in 239
analysed patients with B-cell NHL, despite free treatment,
contributing to 25% of treatment failures, with most patients
abandoning treatment after pre-phase chemotherapy; the
authors postulated that geographic distance from the treat-
ment centre as well as families’ misperceptions of cure after
initial therapy may have contributed to treatment abandon-
ment (Moleti et al, 2011). Interestingly, the authors also
noted treatment abandonment disproportionately affecting
female patients in their analysis, with 12-month cumulative
incidence of abandonment at 22% in females compared to
7% in males (p < 0001)(Moleti et al, 2011). Yao et al
(2012) described the prominent challenge of treatment aban-
donment in Côte d’Ivoire, where nearly half of the children
presenting with cancer abandoned treatment shortly after the
first admission, resulting in only a 6% cure rate for Burkitt
lymphoma. In Sierra Leone, despite shortening the duration
of inpatient treatment, providing free treatment with provi-
sions for meals and transportation, treatment abandonment
was found to be a persistent challenge in rural areas without
an accessible quality referral network (San Roman et al,
2013). While often described as a challenge for patients with
NHL, several studies have suggested that treatment abandon-
ment may be relatively lower for patients with NHL than
those with other diagnoses. In a retrospective cohort analysis
in Shanghai, China, abandonment affected 115% of 108
patients with lymphoblastic lymphoma, which, the authors
noted, was less than the abandonment rates of 135–513%
in patients with acute lymphoblastic leukaemia over the
same time period in Shanghai (Gao et al, 2014). Of patients
with ALCL treated across 6 AHOPCA countries between
2000 and 2013 (n = 31), 65% abandoned therapy, some-
what lower than the abandonment rate typically experienced
with other tumours in the same settings (Ceppi et al, 2016).
It is possible that abandonment rates in aggressive lym-
phomas may be lower given the shorter treatment duration
(than for leukaemia, for instance) and children are too
acutely unwell to be discharged during therapy and thus
have less opportunity to abandon treatment. The finding
that children with lymphoma may be less likely to abandon
treatment upfront, or refuse therapy before starting any
treatment, was further noted in a retrospective analysis from
Guatemala (Alvarez et al, 2017), where 21% of 1789 children
abandoned therapy over an 8-year period; a lymphoma diag-
nosis was associated with a lower likelihood to refuse ther-
apy (Z score 0686, P = 003) without an associated lower
likelihood in later treatment abandonment. Complex factors
can contribute to treatment abandonment, as reported by
families in home-based interviews in a study in Kenya, in
which NHL patients comprised just over half the study
cohort; these factors included advice from others to seek
complementary and alternative therapy, and concern over
hospital detention due to inability to pay hospital bills (Mos-
tert et al, 2014). However, systemic support is paramount,
with another retrospective study demonstrating that treat-
ment abandonment was the most common cause of treat-
ment failure for children with NHL in Kenya, affecting 35%
of patients, where health insurance access was associated
with improved outcomes (Martijn et al, 2017). Early pre-
emptive strategies may be helpful. In El Salvador, in addition
to free treatment, implementation of a tracking protocol for
missed appointments (before patients met criteria for treat-
ment abandonment) successfully prevented treatment aban-
donment in the majority of patients, including patients with
lymphomas, and similar strategies have proven effective in
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many settings (Salaverria et al, 2015; Suarez et al, 2015)
(Fig 3).
Limited guidelines and guidance documents
National guidelines for the management of NHL in children
are warranted, and ideally would be developed by a defined
process of evidence synthesis (including consideration of the
local health system context and data from local research),
and supported by a sound infrastructure for ongoing moni-
toring and continuous quality improvement (Thacker et al,
2017). Unfortunately, a paucity of local data, lack of infras-
tructure for clinical research and continuous quality
improvement, and lack of funding for and prioritization of
local guideline development delay the arrival of locally devel-
oped evidence, and recommendations developed in HIC
contexts do not consider issues like abandonment and high
rates of toxic death. For these reasons, national cancer con-
trol plans in resource-limited settings have not traditionally
prioritized clinical research, but this is changing rapidly
(Weaver et al, 2015). For example, using a Delphi consensus
methodology, the Colombia Ministry of Health and Social
Protection has published a clinical practice guideline for
children and adolescents with NHL and Hodgkin lymphoma,
using defined methods including GRADE to categorize rec-
ommendations (Ministerio de Salud y Proteccion Social –
Colciencias, 2013). Some national efforts have explicitly
identified the need for cross-sector engagement, such as rec-
ognizing the need for partnership with oral health providers
to ensure timely recognition and referral of Burkitt lym-
phoma in Sierra Leone as part of national essential services
(Ministry of Health and Sanitation, Sierra Leone, 2010, San
Roman et al, 2013). In addition, multi-country collaborative
efforts in research and quality improvement have advanced
care and improved the local evidence base substantially. The
experience of GFAOP and AHOPCA has shown how regio-
nal collaborative prospective protocols can be successfully
implemented in resource-limited settings, including in sub-
Saharan Africa (Traore et al, 2011; Pe~na-Hernandez et al,
2019).
Conclusions and future directions
Mature B-cell lymphomas are curable in 90% of cases using
conventional high-dose chemotherapy regimens that com-
prise widely-available inexpensive generic drugs administered
according to the patient’s risk group. Risk stratification is
tailored to disease burden, as practiced in HIC. In LMIC,
lack of diagnosis, misdiagnosis, advanced disease, abandon-
ment and toxic death from comorbidities, such as malnutri-
tion and infections, result in cure rates much lower than
those in HIC. In LIC, only mild chemotherapy that cures
about 50% of children is feasible; whereas in MIC the use of
locally adapted high-dose therapies cures 70–80% cure in
UMIC and 60–70% in lower-MIC. However, the toxic death
rate in these settings still greatly exceeds the 1–3% rates in
HIC. Accurate diagnosis, improved supportive care, and the
introduction of new less toxic drugs, such as rituximab, and
improved supportive care with granulocyte-stimulating
growth factors and rasburicase, may improve results world-
wide. Tackling treatment abandonment and strengthening
the health system to facilitate the completion of treatment in
children while avoiding financial or social catastrophe would
further improve the results in these highly curable children,
especially in LMIC.
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